ELANElanco Animal Health Incorporated
Is it safe?
Forensics clean, with a caveat: clean books and insiders buying, but big price swings.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Multiple insiders bought with their own money (net +$1.5M, 90 days to Oct 8, 2026).
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -78% · now 15% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ELAN take a bad year?
The deepest fall in ELAN's price history on file is −78%; it is 15% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand
- Debt / equity
- 0.59×
Debt / equity
- Annualised volatility
- 47%
Annualised volatility · roughly twice as jumpy as the market
- Worst drawdown on file
- −78%
Worst drawdown on file · −15% today
Details›
- Total debtQ2 2026
- $3.92B
- Cash and short-term investments
- $530M
- Net debt
- $3.39B
- Debt / equity
- 0.59×
- Annualised volatilitytwo years of daily moves
- 47%
- Worst drawdown on file
- −78%
- Below its 52-week high
- 15%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #20 of 41 by RyuScore